Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...
Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...
Fenebrutinib numerically reduced the risk of disability progression by 12% compared to OCREVUS as early as 24 weeks; additional analysis showed potential benefit in upper limb function Fenebrutinib ...
An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS). University of Queensland researcher Dr Christian Gruber said the ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...
VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
In just a few years, multiple sclerosis patients may have the option of taking an oral medication rather than injections. About 400,000 Americans acknowledge having MS, a condition that affects the ...
In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were ...
This development continues a positive operational trend for the company in early 2026. In late January, BioNxt reported that its Cladribine ODF program for multiple sclerosis demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results